Trials / Terminated
TerminatedNCT00333060
Study of OT-551 Eye Drops to Prevent or Delay Progression of Nuclear Cataracts Following Vitreous Removal
Phase 2 Study of OT-551 Ophthalmic Solution to Prevent or Delay Progression of Nuclear Cataract Formation In Post-Vitrectomy Patients
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 164 (estimated)
- Sponsor
- Othera Pharmaceuticals · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to compare the ability of two doses of OT-551 ophthalmic solution and drug-free solution to safely and effectively prevent or delay the progression of nuclear cataracts that frequently develop as a result of vitrectomy (surgery for retina repair), thereby avoiding the need for a second surgery (cataract removal). Victrectomies involve removal of the jelly-like substance (vitreous) that is located in a cavity behind the lens.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OT-551 ophthalmic solution |
Timeline
- Start date
- 2005-11-01
- Completion
- 2008-01-01
- First posted
- 2006-06-02
- Last updated
- 2008-04-02
Locations
16 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00333060. Inclusion in this directory is not an endorsement.